Aetos has exclusive license for the Celltheon SMARTTM Expression Platform, a robust mammalian cell expression system that has been validated on several clinical stage molecules (novel and biosimilar).

  • Technologies that involve novel DNA/ RNA elements in expression vector (patent pending)
  • Aetos generates cell lines producing >4g/L.
  • >70% of Aetos’ clones are stable for 60+ generations.
  • Final process with >95% matching of key CQAs to the innovator molecule.